Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
3-Guanidinopropionic acid is a creatine analog that alters skeletal muscle energy expenditure. It reduces cellular ATP, creatine, and phosphocreatine levels and stimulates AMP-activated protein kinase (AMPK), activating PPARγ coactivator 1α (PGC-1α).1,2,3,4 PGC-1α activation results in enhanced expression of AMPK, as well as genes for oxidative phosphorylation, electron transport chain, and mitochondrial biogenesis, increasing oxidative muscle fibers, numbers of mitochondria, and motor performance.1,5 3-Guanidinopropionic acid evokes a shift from glycolytic to oxidative metabolism, increased cellular glucose uptake, and increased fatigue tolerance.2 In aged rats, reduced mitochondrial biogenesis in response to chronic activation of AMPK with 3-guanidinopropionic acid leads to metabolic insufficiency that can contribute to muscle loss.6,5
WARNING This product is not for human or veterinary use.
1. Impaired PGC-
2. The effect of the creatine analogue beta-
3. Biochemical adaptation in the skeletal muscle of rats depleted of creatine with the substrate analogue β-
4. Creatine transporter activity and content in the rat heart supplemented by and depleted of creatine. Am. J. Physiol. Endocrinol. Metab. 284(2), E399-E406 (2003).
5. Aging-
6. Mitochondrial biogenesis drives a vicious cycle of metabolic insufficiency and mitochondrial DNA deletion mutation accumulation in aged rat skeletal muscle fibers. PLoS One 8(3), 1-8 (2013).